ACADIA PHARMACEUTICALS INC. news, videos and press releases - Page 5
For more news please use our advanced search feature.
ACADIA PHARMACEUTICALS INC. - More news...
ACADIA PHARMACEUTICALS INC. - More news...
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
- Shareholder Alert: Robbins LLP Is Investigating Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Shareholders
- SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- ACAD Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed
- Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
- ACADIA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
- Pomerantz Law Firm Announces the Filing of a Class Action against Acadia Pharmaceuticals Inc. and Certain Officers - ACAD
- Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys
- Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys
- Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
- Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
- Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
- Acadia Pharmaceuticals Announces Commercial Leadership Change
- Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
- Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
- Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
- Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
- Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
